Soleno Therapeutics

$2.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-4.74%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SLNO and other stocks, options, and ETFs commission-free!

About SLNO

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA. The listed name for SLNO is Soleno Therapeutics, Inc. Common Stock.

CEO

Anish Bhatnagar

Employees

Headquarters

Redwood City, California

Founded

1999

Market Cap

202.49M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

307.05K

High Today

$2.59

Low Today

$2.41

Open Price

$2.55

Volume

201.37K

52 Week High

$4.39

52 Week Low

$1.30

SLNO News

BenzingaFeb 23

Soleno Therapeutics, Vanderbilt University In Research Pact For K Channel Activators

Soleno Therapeutics Inc (NASDAQ: SLNO) has signed a collaboration agreement with Vanderbilt University for the discovery and development of KATP channel activat

SLNO Earnings

-$0.36

-$0.23

-$0.10

$0.03

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 12, After Hours